|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Zeng H, Zhang S and He J:
Annual report on status of cancer in China, 2011. Chin J Cancer
Res. 27:2–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wei J, Wang Z, Makarov D and Li X: Current
treatments and novel therapeutic targets for castration resistant
prostate cancer with bone metastasis. Am J Clin Exp Urol. 1:30–38.
2013.PubMed/NCBI
|
|
4
|
Kelly BD, Miller N, Sweeney KJ, Durkan GC,
Rogers E, Walsh K and Kerin MJ: A circulating MicroRNA signature as
a biomarker for prostate cancer in a high risk group. J Clin Med.
4:1369–1379. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pillai RS: MicroRNA function: Multiple
mechanisms for a tiny RNA? RNA. 11:1753–1761. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang HD, Jiang LH, Sun DW, Li J and Tang
JH: MiR-139-5p: Promising biomarker for cancer. Tumour Biol.
36:1355–1365. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu W, Hang M, Yuan CY, Wu FL, Chen SB and
Xue K: MicroRNA-139-5p inhibits cell proliferation and invasion by
targeting insulin-like growth factor 1 receptor in human non-small
cell lung cancer. Int J Clin Exp Pathol. 8:3864–3870.
2015.PubMed/NCBI
|
|
9
|
Zhang L, Dong Y, Zhu N, Tsoi H, Zhao Z, Wu
CW, Wang K, Zheng S, Ng SS, Chan FK, et al: microRNA-139-5p exerts
tumor suppressor function by targeting NOTCH1 in colorectal cancer.
Mol Cancer. 13:1242014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang HD, Sun DW, Mao L, Zhang J, Jiang
LH, Li J, Wu Y, Ji H, Chen W, Wang J, et al: MiR-139-5p inhibits
the biological function of breast cancer cells by targeting Notch1
and mediates chemosensitivity to docetaxel. Biochem Biophys Res
Commun. 465:702–713. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cammaerts S, Strazisar M, de Rijk P and
Del Favero J: Genetic variants in microRNA genes: Impact on
microRNA expression, function, and disease. Front Genet. 6:1862015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou Y, Du WD, Chen G, Ruan J, Xu S, Zhou
FS, Zuo XB, Lv ZJ and Zhang XJ: Association analysis of genetic
variants in microRNA networks and gastric cancer risk in a Chinese
Han population. J Cancer Res Clin Oncol. 138:939–945. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen B, Li H, Zeng X, Yang P, Liu X, Zhao
X and Liang S: Roles of microRNA on cancer cell metabolism. J
Transl Med. 10:2282012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo
ZY, Zhao J, Meng YL, Ren XL, Wang T, et al: HER2 interacts with
CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139
in gastric cancer cells. Gastroenterology. 141:2076–2087.e6. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen K, Mao R, Ma L, Li Y, Qiu Y, Cui D,
Le V, Yin P, Ni L and Liu J: Post-transcriptional regulation of the
tumor suppressor miR-139-5p and a network of miR-139-5p-mediated
mRNA interactions in colorectal cancer. FEBS J. 281:3609–3624.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Krishnan K, Steptoe AL, Martin HC,
Pattabiraman DR, Nones K, Waddell N, Mariasegaram M, Simpson PT,
Lakhani SR, Vlassov A, et al: miR-139-5p is a regulator of
metastatic pathways in breast cancer. RNA. 19:1767–1780. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li T, Yin J, Yuan L, Wang S, Yang L, Du X
and Lu J: Downregulation of microRNA-139 is associated with
hepatocellular carcinoma risk and short-term survival. Oncol Rep.
31:1699–1706. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li RY, Chen LC, Zhang HY, Du WZ, Feng Y,
Wang HB, Wen JQ, Liu X, Li XF, Sun Y, et al: MiR-139 inhibits Mcl-1
expression and potentiates TMZ-induced apoptosis in glioma. CNS
Neurosci Ther. 19:477–483. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song M, Yin Y, Zhang J, Zhang B, Bian Z,
Quan C, Zhou L, Hu Y, Wang Q, Ni S, et al: MiR-139-5p inhibits
migration and invasion of colorectal cancer by downregulating AMFR
and NOTCH1. Protein Cell. 5:851–861. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deng G, Ma L, Meng Q, Ju X, Jiang K, Jiang
P and Yu Z: Notch signaling in the prostate: Critical roles during
development and in the hallmarks of prostate cancer biology. J
Cancer Res Clin Oncol. 142:531–547. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cohen B, Shimizu M, Izrailit J, Ng NF,
Buchman Y, Pan JG, Dering J and Reedijk M: Cyclin D1 is a direct
target of JAG1-mediated Notch signaling in breast cancer. Breast
Cancer Res Treat. 123:113–124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hsu TI, Lin SC, Lu PS, Chang WC, Hung CY,
Yeh YM, Su WC, Liao PC and Hung JJ: MMP7-mediated cleavage of
nucleolin at Asp255 induces MMP9 expression to promote tumor
malignancy. Oncogene. 34:826–837. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wong VW, Garg RK, Sorkin M, Rustad KC,
Akaishi S, Levi K, Nelson ER, Tran M, Rennert R, Liu W, et al: Loss
of keratinocyte focal adhesion kinase stimulates dermal proteolysis
through upregulation of MMP9 in wound healing. Ann Surg.
260:1138–1146. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kato H and Nishitoh H: Stress responses
from the endoplasmic reticulum in cancer. Front Oncol. 5:932015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fan P, Cunliffe HE, Maximov PY, Agboke FA,
McDaniel RE, Zou X, Ramos P, Russell ML and Jordan VC: Integration
of downstream signals of insulin-like growth factor-1 receptor by
endoplasmic reticulum stress for estrogen-induced growth or
apoptosis in breast cancer cells. Mol Cancer Res. 13:1367–1376.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mihelich BL, Maranville JC, Nolley R,
Peehl DM and Nonn L: Elevated serum microRNA levels associate with
absence of high-grade prostate cancer in a retrospective cohort.
PLoS One. 10:e01242452015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun X, Yang Z, Zhang Y, He J, Wang F, Su
P, Han J, Song Z and Fei Y: Prognostic implications of tissue and
serum levels of microRNA-128 in human prostate cancer. Int J Clin
Exp Pathol. 8:8394–8401. 2015.PubMed/NCBI
|
|
29
|
Guo J, Wang M and Liu X: MicroRNA-195
suppresses tumor cell proliferation and metastasis by directly
targeting BCOX1 in prostate carcinoma. J Exp Clin Cancer Res.
34:912015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu J, Ji A, Wang X, Zhu Y, Yu Y, Lin Y,
Liu Y, Li S, Liang Z, Xu X, et al: MicroRNA-195-5p, a new regulator
of Fra-1, suppresses the migration and invasion of prostate cancer
cells. J Transl Med. 13:2892015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao W, Cao L, Zeng S, Qin H and Men T:
Upregulation of miR-556-5p promoted prostate cancer cell
proliferation by suppressing PPP2R2A expression. Biomed
Pharmacother. 75:142–147. 2015. View Article : Google Scholar : PubMed/NCBI
|
